

**Neuland Laboratories Limited**  
11th floor (5th level), Phoenix IVY Building,  
Plot No.573A-III, Road No.82, Jubilee Hills,  
Hyderabad-500033, Telangana, India.



CONTACT  
040 6761 1600 / 6761 1700  
neuland@neulandlabs.com  
neulandlabs.com

February 11, 2025

To  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai – 400 001

**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANDLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Copies of newspaper advertisement regarding financial results of the Company for the quarter and nine months ended December 31, 2024**

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, please find enclosed copies of newspaper advertisement regarding the Financial Results of the Company for the quarter and nine months ended December 31, 2024, as published in Financial Express and Andhra Prabha on February 11, 2025.

This is for your information and records.

Yours sincerely,  
For **Neuland Laboratories Limited**

**Sarada Bhamidipati**  
**Company Secretary**

*Encl: As above*





ICICI Prudential Asset Management Company Limited

Corporate Identity Number: U11999DL1993PLC034138

Registered Office: 12th Floor, Narain Manzil, 23, Barakhamba Road, New Delhi - 110 001. Corporate Office: ONE BKC, A Wing, 13th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051. Tel: +91 22 2652 5000, Fax: +91 22 2652 8100.

Notice to the Investors/Unit holders of ICICI Prudential Commodities Fund (the Scheme)

Notice is hereby given that ICICI Prudential Trust Limited, Trustee to ICICI Prudential Mutual Fund has approved the following distribution under Income Distribution cum capital withdrawal option (IDCW option) of the Scheme, subject to availability of distributable surplus on the record date i.e. on February 13, 2025:

Table with 3 columns: Name of the Scheme/Plans, Quantum of IDCW per unit, NAV as on February 7, 2025.

The distribution will be subject to the availability of distributable surplus and may be lower depending upon the extent of distributable surplus available on the record date under the IDCW option of the Scheme.

Subject to deduction of applicable statutory levy, if any or the immediately following Business Day, if that day is a Non-Business Day.

The distribution with respect to IDCW will be done to all the unit holders/beneficial owners whose names appear in the register of unit holders/Statement of beneficial owners maintained by the Depositories, as applicable under the IDCW option of the Scheme, at the close of business hours on the record date.

It should be noted that pursuant to payment of IDCW, the NAV of the IDCW option of the Scheme would fall to the extent of payout and statutory levy (if applicable).

For ICICI Prudential Asset Management Company Limited

Place: Mumbai Date: February 10, 2025

To know more, call 1800 222 999/1800 200 6666 or visit www.icicipruamc.com Investors are requested to periodically review and update their KYC details along with their mobile number and email id.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Pipeline Infrastructure Limited

Registered Office: Seawoods Grand Central, Tower 1, 3rd Level, C Wing - 301 to 304, Sector 40, Seawoods Railway Station, Navi Mumbai, Thane, Maharashtra - 400706, India.

EXTRACT OF FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024

Table with 4 columns: Sr No, Particulars, Quarter ended December 31, 2024, Quarter ended December 31, 2023, Year ended March 31, 2024.

\* Includes fair valuation loss on Non-Convertible Debentures, measured at Fair value through profit or loss of Rs. 306.03 Crore and gain of Rs. 9.37 Crore for the quarter ended December 31, 2024 and December 31, 2023 respectively and loss of Rs. 633.82 Crore for year ended March 31, 2024.

Table with 4 columns: Particulars, As at December 31, 2024, As at March 31, 2024.

Debiture Redemption Reserve (DRR) is not required to be created due to absence of profits available for payment of dividend. The Company has accumulated losses as at December 31, 2024.

Date: February 10, 2025 Place: Navi Mumbai



Regd Office: 3rd Floor, A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai - 400701.

EXTRACT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024

Table with 5 columns: Sr. No, Particulars, Quarter ended 01/10/2024 to 31/12/2024, Year to date figures 01/04/2024 to 31/12/2024, Previous Year ending 31/03/2024, Corresponding 3 months ended in the previous year 01/10/2023 to 31/12/2023.

The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10th February, 2025 pursuant to regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

Date: 10/02/2025 Place: Navi Mumbai



Total Income of Rs. 177.75 Cr for Q3 FY25 ✓ EBIDTA of Rs. 33.37 Cr for Q3 FY25 ✓ PAT of Rs. 16.33 Cr for Q3 FY25

Extract of Un-Audited Financials Results for the Quarter and Nine Months Ended December 31, 2024

Table with 7 columns: S. No, PARTICULARS, Quarter ended 31 Dec, 2024, Nine Months ended 31 Dec, 2024, Quarter ended 31 Dec, 2023, Quarter ended 31 Dec, 2024, Nine Months ended 31 Dec, 2024, Quarter ended 31 Dec, 2023.

The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.

Registered and Corporate Office: 148, Technocrats Industrial Estate, Balanagar, Hyderabad 500 037, Telangana, India; Tel: +91 40 4455 3333; E-mail: naina.singh@mtar.in; Website: www.mtar.in;

K.C.P.SUGAR AND INDUSTRIES CORPORATION LIMITED

Registered Office: 'Ramakrishna Buildings', No.239, Anna Salai, Chennai - 600 006

EXTRACT OF THE STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31.12.2024 PURSUANT TO REGULATION 47 OF SEBI (LODR) REGULATIONS, 2015

Table with 10 columns: S. No, PARTICULARS, Quarter Ended 31.12.2024, Nine Months Ended 31.12.2024, Year Ended 31.03.2024, Quarter Ended 31.12.2023, Nine Months Ended 31.12.2023, Year Ended 31.03.2023.

1. Sugar industry being a seasonal industry and of a predominantly cyclical nature, the above results can neither be construed as an indicator of the overall annual operations and profitability of the Company nor for inter-annual comparison between quarters within a financial year.

The Statutory Auditor of the Company has carried out a Limited Review of the above Standalone and Consolidated Financial Results for the Quarter / Nine Months ended 31.12.2024 and their report was placed before the Board.

The above is an extract of the detailed format of Quarterly / Nine Months ended Unaudited Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

NEULAND LABORATORIES LIMITED

Regd. Office: 11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

Table with 7 columns: Sl. No, Particulars, Quarter Ended 31.12.2024, Quarter Ended 30.09.2024, Quarter Ended 31.12.2023, Nine Months Ended 31.12.2024, Nine Months Ended 31.12.2023, Year Ended 31.03.2024.

Note 1: The financial results for the quarter and nine months ended December 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 10, 2025.

Table with 7 columns: Particulars, Quarter Ended 31.12.2024, Quarter Ended 30.09.2024, Quarter Ended 31.12.2023, Nine Months Ended 31.12.2024, Nine Months Ended 31.12.2023, Year Ended 31.03.2024.

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Date: Hyderabad Date: February 10, 2025

LUMAX INDUSTRIES LIMITED

Regd. Office: 2nd Floor, Harbans Bhawan-II, Commercial Complex, Nagajaya, New Delhi-110046

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE 3rd QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

Table with 4 columns: Particulars, Quarter ended December 31, 2024, Nine Months ended December 31, 2024, Quarter ended December 31, 2023.

Note 1: The above unaudited consolidated financial results of Lumax Industries Limited ("The Holding Company") and its subsidiary (together referred to as "the Group") and its associate have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held today i.e. February 10, 2025.

Note 2: The above is an extract of the detailed format of Financial Results for the Quarter and nine months ended December 31, 2024 filed with the Stock Exchanges under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Place: Gurugram Date: February 10, 2025



